HIRA gave notice of health insurance benefits for Keytruda and Opdivo

The Health Insurance Review & Assurance Service(President Seung-Taek Kim, HIRA) decided a revision bill for the ‘Details of Health Insurance Benefit Application Standards and Methods for Drugs Prescribed and Used for Cancer Patients,’ which create health insurance benefit standards for Keytruda(generic name: pembrolizumab) and Opdivo(nivolumab), immune checkpoint inhibitors.

In order to prepar...